Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management
Raj Chovatiya, M.D., Ph.D. and Neal Bhatia, MD comment on the importance of assessing a treatment’s available clinical trial data, ability to control disease severity, and QoL impacts when assessing atopic dermatitis treatment options.
EP: 1.Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments
EP: 2.Atopic Dermatitis Treatment Biological Targets
EP: 3.Use of JAK Inhibitors in Clinical Practice
Now Viewing
EP: 4.Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management
EP: 5.Final Thoughts for Atopic Dermatitis Treatment
EP: 6.Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 7.Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 8.Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 9.Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 10.Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 11.Expert Perspective on the Care of Patients with Atopic Dermatitis
EP: 12.Role of Disease Severity in Topical vs Systemic AD Treatment
EP: 13.Efficacy and Safety of JAK inhibitors for AD
EP: 14.Optimizing Patient Outcomes with JAK Inhibitors
Related Videos
Related Content
